|
|
|
|
Army Of New Care Advisors Joins The Fight Against Muscle Disease, UK
An army of 19 new and newly secured care advisors will be joining the fight against muscle disease across the UK with the Muscular Dystrophy Campaign.Thanks to the hard work of campaigning patients in 10 UK regions and the Muscular ...
|
|
|
Medical News: Army Of New Care Advisors Joins The Fight Against Muscle Disease, UK
An army of 19 new and newly secured care advisors will be joining the fight against muscle disease across the UK with the Muscular Dystrophy Campaign.Medical News: Army Of New Care Advisors Joins The Fight Against Muscle Disease, UK.
|
|
|
Muscular Dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016
Summary Muscular dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global muscular dystrophy market.The report identifies the key trends shaping and driving the global ...
|
|
|
Diary Note: East Of England Muscle Disease Conference
What Families living with muscle disease in the East of England are joining forces with clinicians and MPs at an inaugural conference for the region, organised by the Muscular Dystrophy Campaign.The conference will be an opportunity for families...
|
|
|
PTC Therapeutics/Genzyme's ataluren fails in Phase IIb muscular dystrophy trial
PTC Therapeutics and Genzyme's ataluren, an experimental nonsense mutation suppressor, has failed in nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDB PTC Therapeutics/Genzyme's ataluren fails in Phase IIb muscular dystrophy trial.<...
|
|
|
Medical News: Diary Note: East Of England Muscle Disease Conference
What Families living with muscle disease in the East of England are joining forces with clinicians and MPs at an inaugural conference for the region, organised by the Muscular Dystrophy Campaign.The conference will be an opportunity for families...
|
|
|
Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released ..
Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released Refer to a friend 2010-03-10 12:13:04 - Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and...
|
|
|
Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new
www.companiesandmarkets.com/Summary-Company-Profile/santhera-pha ..Santhera Pharmaceuticals Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call
(MARKETWIRE via COMTEX) ----AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Tuesday, March 16, 2010. Subsequently, at 8:30 a.m.
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call
(MARKETWIRE via COMTEX) ----AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Tuesday, March 16, 2010. Subsequently, at 8:30 a.m.
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call
Companies mentioned in this article: AVI BioPharma, Inc.BOTHELL, WA -- (Marketwire) -- 03/09/10 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will report fourth quarter and full year 2009 financial results before the NASDAQ Global...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financi...
Company: AVI BioPharma, Inc.(AVII) AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Tuesday, March 16, 2010. Subsequently, at 8:30...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call
The conference call may be accessed by dialing 866.578.5771 for domestic callers and 617.213.8055 for international callers.The passcode for the call is 39302987 and please specify to the operator that you would like to join the "AVI BioPharma fourth quarter...
|
|
|
Isis Pharma to get $6M milestone payment
Isis Pharmaceuticals Inc.said Monday it will get $6 million from Bristol-Myers Squibb as a milestone payment for a drug it is helping to develop. The company has also independently launched a human study of another drug. The Bristol-Myers drug, called...
|
|
|
Isis Pharma to get $6M milestone payment
Isis Pharmaceuticals Inc.said Monday it will get $6 million from Bristol-Myers Squibb as a milestone payment for a drug it is helping to develop. The company has also independently launched a human study of another drug. The Bristol-Myers drug, called...
|
|
|
Isis Pharma to get $6M milestone payment [North County Times, Escondido, Calif.]
8--CARLSBAD -- Isis Pharmaceuticals Inc.said Monday it will get $6 million from Bristol-Myers Squibb as a milestone payment for a drug it is helping to develop. The company has also independently launched a human study of another drug. The Bristol-Myers...
|
|
|
Isis Pharma starts phase-I trial of Isis-SODIRx in patients with neurodegenerative disease
Isis Pharmaceuticals, Inc has initiated a phase-1 study of Isis-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).Approximately 20 per cent of all familial ALS cases are...
|
|
|
ISIS Initiates Neurodegenerative Drug Trials
Isis Pharmaceuticals has initiated Phase I studies of ISIS-SOD1Rx to treat patients with an inherited aggressive form of Lou Gehrig's disease, also known as familial amyotrophic lateral sclerosis (ALS).Approximately 20% of all familial ALS cases are caused...
|
|
|
Cantor Fitzgerald Reiterates Isis Pharmaceuticals (ISIS) Buy Rating
Cantor Fitzgerald analyst Pamela Bassett reiterated her Buy rating for shares of Isis Pharmaceuticals, Inc.(Nasdaq: ISIS ), with a price target of $28. Bassett noted that ISIS-SOD1Rx has been granted Orphan Drug designation by the FDA and funding from the...
|
|
|
Medivation, Pfizer Disappointed Over Drug Failure - Biotech's Latest Mishaps
The Burrill Report submits: Pfizer (PFE) and Medivation (MDVN) said dimebon, their experimental drug to treat Alzheimers disease, failed in two late-stage clinical trials.Medivations stock, which had been trading at an all time high of $40.49 right before...
|
|
|
::: Isis Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
Isis' first drug to treat neurodegenerative disease enters clinical trials CARLSBAD, Calif., March 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc.(NASDAQ:ISIS) announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an...
|
|
|
PTC Therapeutics and Genzyme's muscular dystrophy drug ataluren fails to meet endpoint in phase-2b trial
PTC Therapeutics, Inc and Genzyme Corporation announced preliminary results from the phase-2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD).The primary...
|
|
|
ISIS Initiates Phase 1 Clinical Trial Of ISIS-SOD1Rx In Patients With ALS
Isis Pharmaceuticals, Inc.(Nasdaq: ISIS) announced that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS). Approximately 20...
|
|
|
PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Atal
TC Therapeutics, Inc.and Genzyme Corporation announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD). The primary...
|
|
|
ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
CARLSBAD, Calif., March 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc.(Nasdaq: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial...
|
